At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
In Brief
A Phase 2 clinical trial evaluating Cabozantinib S-malate and Laboratory Biomarker Analysis for Metastatic Ewing Sarcoma and 9 related conditions. Active but no longer recruiting, targeting 90 participants across 11 sites.
Signals
Detailed Summary
This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may also prevent the growth of new blood vessels that tumors need to grow.
Study Details
Timeline
Arms & Interventions
Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Interventions
Given PO
Correlative studies